Osiris Therapeutics, a US-based stem cell company, has expanded its Grafix product portfolio with the launch of several new sizes.
Produced by Osiris Therapeutics’ BioSmart Intelligent Tissue Processing, Grafix is a flexible, cryopreserved placental membrane for acute and chronic wounds. The conforming membrane is applied directly at the site of the wound.
Grafix, which is now available in five convenient sizes, gives health care providers the ability to optimally match Grafix to the wound size, reduce overall treatment costs and eliminate concerns regarding product waste.
Osiris Therapeutics president and CEO Lode Debrabandere said: "Our objective is to deliver the highest quality wound product to providers and their patients suffering from chronic wounds.
"We continue to make tremendous strides with Grafix and look forward to broadening access to more patients now that our pivotal 302 trial has been accepted for publication."
The company is also introducing a delivery system in addition to the launch of multiple new sizes of Grafix. Accorddin to Osiris Therapeutics, the new design reduces thaw time, increases product maneuverability and eases the overall application of Grafix to the wound bed.